{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T19:49:15Z","timestamp":1791143355066,"version":"4.1.0"},"reference-count":33,"publisher":"Spandidos Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.3892\/mco.2014.264","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T13:59:55Z","timestamp":1392904795000},"page":"479-487","source":"Crossref","is-referenced-by-count":14,"title":["Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiation"],"prefix":"10.3892","volume":"2","author":[{"given":"MARK","family":"SHILKRUT","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANGELA","family":"WU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAFYDD G.","family":"THOMAS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DANIEL A.","family":"HAMSTRA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,2,20]]},"reference":[{"key":"key20180107150653_b1-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 1","key":"key20180107150653_b2-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.urology.2006.05.060","article-title":"Radiotherapy for bladder cancer","volume":"69","author":"Milosevic","year":"2007","journal-title":"Urology"},{"key":"key20180107150653_b3-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1200\/JCO.2008.19.5776","article-title":"Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06","volume":"27","author":"Efstathiou","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20180107150653_b4-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.eururo.2011.11.010","article-title":"Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience","volume":"61","author":"Efstathiou","year":"2012","journal-title":"Eur Urol"},{"key":"key20180107150653_b5-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.1996.14.11.2901","article-title":"Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group","volume":"14","author":"Coppin","year":"1996","journal-title":"J Clin Oncol"},{"key":"key20180107150653_b6-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa1106106","article-title":"Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer","volume":"366","author":"James","year":"2012","journal-title":"N Engl J Med"},{"key":"key20180107150653_b7-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1200\/JCO.2010.32.3139","article-title":"International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial","volume":"29","author":"International Collaboration of Trialists","year":"2011","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"key20180107150653_b8-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.urology.2006.10.041","article-title":"Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemo-therapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer","volume":"69","author":"Sternberg","year":"2007","journal-title":"Urology"},{"key":"key20180107150653_b9-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(10)70244-8","article-title":"The ribo-nucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer","volume":"12","author":"Jordheim","year":"2011","journal-title":"Lancet Oncol"},{"key":"key20180107150653_b10-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1111\/j.1464-410X.2010.09327.x","article-title":"Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients","volume":"106","author":"Harshman","year":"2010","journal-title":"BJU Int"},{"key":"key20180107150653_b11-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa065411","article-title":"DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer","volume":"356","author":"Zheng","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107150653_b12-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ctrv.2007.07.001","article-title":"Current status of excision repair cross complementing-group 1 (ERCC1) in cancer","volume":"33","author":"Gossage","year":"2007","journal-title":"Cancer Treat Rev"},{"key":"key20180107150653_b13-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/j.1600-0463.2010.02648.x","article-title":"Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy","volume":"118","author":"Kim","year":"2010","journal-title":"APMIS"},{"key":"key20180107150653_b14-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/1471-2407-12-187","article-title":"ERCC1 as a biomarker for bladder cancer patients likely to benefit from adjuvant chemotherapy","volume":"12","author":"Sun","year":"2012","journal-title":"BMC Cancer"},{"key":"key20180107150653_b15-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1158\/1078-0432.CCR-10-1963","article-title":"Excision repair cross-complementing group 1 may predict the efficacy of chemoradiation therapy for muscle-invasive bladder cancer","volume":"17","author":"Kawashima","year":"2011","journal-title":"Clin Cancer Res"},{"key":"key20180107150653_b16-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.lungcan.2011.08.016","article-title":"RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC","volume":"75","author":"Vilmar","year":"2012","journal-title":"Lung Cancer"},{"key":"key20180107150653_b17-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1016\/j.urolonc.2012.06.014","article-title":"Low ERCC1 expression is associated with prolonged survival in patients with bladder cancer receiving platinum-based neoadjuvant chemotherapy","volume":"31","author":"Ozcan","year":"2012","journal-title":"Urol Oncol"},{"key":"key20180107150653_b18-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"5082","DOI":"10.1128\/MCB.00293-08","article-title":"ERCC1-XPF endonuclease facilitates DNA double-strand break repair","volume":"28","author":"Ahmad","year":"2008","journal-title":"Mol Cell Biol"},{"key":"key20180107150653_b19-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ijc.1385","article-title":"Tissue microarrays (TMAs) for high-throughput molecular pathology research","volume":"94","author":"Nocito","year":"2001","journal-title":"Int J Cancer"},{"key":"key20180107150653_b20-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1016\/j.juro.2008.08.075","article-title":"Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder","volume":"180","author":"Smith","year":"2008","journal-title":"J Urol"},{"key":"key20180107150653_b21-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1002\/cncr.23420","article-title":"Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733","volume":"112","author":"Higano","year":"2008","journal-title":"Cancer"},{"key":"key20180107150653_b22-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2004.10.070","article-title":"Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial","volume":"22","author":"Kent","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180107150653_b23-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.semradonc.2004.07.008","article-title":"Selective bladder preservation by trimodality therapy for patients with muscularis propria-invasive bladder cancer and who are cystectomy candidates - the Massachusetts General Hospital and Radiation Therapy Oncology Group experiences","volume":"15","author":"Shipley","year":"2005","journal-title":"Semin Radiat Oncol"},{"key":"key20180107150653_b24-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1002\/1097-0142(19941115)74:10<2819::AID-CNCR2820741013>3.0.CO;2-L","article-title":"Preoperative radiotherapy for muscle-invasive bladder carcinoma. Long term follow-up and prognostic factors for 338 patients","volume":"74","author":"Pollack","year":"1994","journal-title":"Cancer"},{"key":"key20180107150653_b25-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","article-title":"Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"key":"key20180107150653_b26-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdl300","article-title":"ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine","volume":"17","author":"Ceppi","year":"2006","journal-title":"Ann Oncol"},{"key":"key20180107150653_b27-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1093\/annonc\/mdl435","article-title":"Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy","volume":"18","author":"Bellmunt","year":"2007","journal-title":"Ann Oncol"},{"key":"key20180107150653_b28-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"812398","DOI":"10.1155\/2012\/812398","article-title":"A review of ERCC1 gene in bladder cancer: implications for carcinogenesis and resistance to chemoradiotherapy","volume":"2012","author":"Kawashima","year":"2012","journal-title":"Adv Urol"},{"key":"key20180107150653_b29-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1002\/cncr.26522","article-title":"Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemo-therapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis","volume":"118","author":"Simon","year":"2012","journal-title":"Cancer"},{"key":"key20180107150653_b30-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.cellbi.2009.07.004","article-title":"Relationship between methylation status of ERCC1 promoter and radiosensitivity in glioma cell lines","volume":"33","author":"Liu","year":"2009","journal-title":"Cell Biol Int"},{"key":"key20180107150653_b31-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180107150653_b32-mco-02-03-0479","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.juro.2010.09.015","article-title":"Treatment of muscle invasive bladder cancer: evidence from the National Cancer Database, 2003 to 2007","volume":"185","author":"Fedeli","year":"2011","journal-title":"J Urol"},{"key":"key20180107150653_b33-mco-02-03-0479","article-title":"RTOG 0712 Protocol Information","year":"2012"}],"container-title":["Molecular and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/mco.2014.264\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T15:07:10Z","timestamp":1515337630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/mco.2014.264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,20]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2014,2,20]]},"published-print":{"date-parts":[[2014,5]]}},"alternative-id":["10.3892\/mco.2014.264"],"URL":"https:\/\/doi.org\/10.3892\/mco.2014.264","relation":{},"ISSN":["2049-9450","2049-9469"],"issn-type":[{"value":"2049-9450","type":"print"},{"value":"2049-9469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,20]]}}}